Increased inflammatory mediators levels are associated with clinical outcomes and prolonged illness in severe COVID-19 patients
Authors:
- 8 August 2023
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 123, 110762
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Severity of chronic obstructive pulmonary disease with ‘exacerbator with emphysema phenotype’ is associated with potential biomarkersPostgraduate Medical Journal, 2019
- High Serum Fractalkine/CX3CL1 in Patients with Chronic Obstructive Pulmonary Disease: Relationship with Emphysema Severity and Frequent ExacerbationLung, 2018
- Fractalkine induces angiogenic potential in CX3CR1-expressing monocytesJournal of Leukocyte Biology, 2017
- Influence of aspirin on the CX3CL1/CX3CR1 signaling pathway in acute pulmonary embolismInternational Journal of Molecular Medicine, 2017
- Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) StudyAmerican Journal of Kidney Diseases, 2015
- T lymphocytes and fractalkine contribute to myocardial ischemia/reperfusion injury in patientsJournal of Clinical Investigation, 2015
- Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathwayActa Pharmacologica Sinica, 2013
- CX3CL1 Is Neuroprotective in Permanent Focal Cerebral Ischemia in RodentsThe Journal of Neuroscience, 2011
- Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in miceAmerican Journal of Physiology-Renal Physiology, 2008
- Heparin Inhibits IFN-γ-Induced Fractalkine/CX3CL1 Expression in Human Endothelial CellsInflammation, 2004